Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 131.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,237 shares of the medical research company’s stock after buying an additional 9,797 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Edwards Lifesciences were worth $1,314,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Sequoia Financial Advisors LLC raised its stake in Edwards Lifesciences by 11.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after purchasing an additional 941 shares during the last quarter. Zions Bancorporation N.A. raised its stake in Edwards Lifesciences by 34.7% in the 1st quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after purchasing an additional 448 shares during the last quarter. Covestor Ltd raised its stake in Edwards Lifesciences by 18.2% in the 1st quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 188 shares during the last quarter. Mather Group LLC. raised its stake in Edwards Lifesciences by 53.5% in the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after purchasing an additional 2,503 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in Edwards Lifesciences by 3.1% in the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after purchasing an additional 19,798 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $86.27 on Thursday. The stock has a market cap of $51.93 billion, a PE ratio of 37.93, a P/E/G ratio of 4.46 and a beta of 1.05. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The stock has a fifty day simple moving average of $90.12 and a 200-day simple moving average of $78.14.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 EPS. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the transaction, the director now owns 4,486 shares in the company, valued at approximately $414,596.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock worth $17,166,254 in the last three months. 1.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Oppenheimer increased their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Stifel Nicolaus raised their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research note on Wednesday, February 7th. Citigroup raised their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Finally, Evercore ISI raised their target price on Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.